Published in Gut on February 27, 2008
Clonal evolution in cancer. Nature (2012) 11.07
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell (2012) 2.16
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies. Surg Endosc (2011) 2.04
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet (2015) 1.89
The human squamous oesophagus has widespread capacity for clonal expansion from cells at diverse stages of differentiation. Gut (2014) 1.49
Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35
Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prev Res (Phila) (2011) 1.21
Dpp signaling determines regional stem cell identity in the regenerating adult Drosophila gastrointestinal tract. Cell Rep (2013) 1.09
Diagnosis and management of Barrett's oesophagus. BMJ (2010) 1.04
Spatial structure increases the waiting time for cancer. New J Phys (2011) 1.02
Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol (2010) 0.98
NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet (2013) 0.98
Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther (2013) 0.96
New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management. Clin Cancer Res (2011) 0.96
Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer (2010) 0.91
Barrett esophagus: what a mouse model can teach us about human disease. Cell Cycle (2012) 0.90
DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res (2012) 0.90
Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists. Am J Surg Pathol (2016) 0.88
Biology of Barrett's esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am (2011) 0.88
Identification of Distinct Tumor Subpopulations in Lung Adenocarcinoma via Single-Cell RNA-seq. PLoS One (2015) 0.88
Emerging optical methods for surveillance of Barrett's oesophagus. Gut (2015) 0.88
Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer (2016) 0.87
Review: Experimental models for Barrett's esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver Physiol (2012) 0.85
The GCTM-5 epitope associated with the mucin-like glycoprotein FCGBP marks progenitor cells in tissues of endodermal origin. Stem Cells (2012) 0.84
Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet (2009) 0.84
Passenger mutations as a marker of clonal cell lineages in emerging neoplasia. Semin Cancer Biol (2010) 0.83
Tumour Cell Heterogeneity. F1000Res (2016) 0.83
Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark (2010) 0.83
Gastrointestinal stem cells in health and disease: from flies to humans. Dis Model Mech (2016) 0.82
Clinical puzzle: Barrett's oesophagus. Dis Model Mech (2008) 0.82
Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology (2015) 0.81
MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium. Cancer Epidemiol Biomarkers Prev (2015) 0.81
Ductal metaplasia in oesophageal submucosal glands is associated with inflammation and oesophageal adenocarcinoma. Histopathology (2015) 0.81
Dissecting out the genetic origins of Barrett's oesophagus. Gut (2008) 0.80
Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus (2013) 0.78
Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma. Virchows Arch (2011) 0.78
Risk factors for neoplastic progression in Barrett's esophagus. World J Gastroenterol (2011) 0.77
Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun (2016) 0.77
Ductular and proliferative response of esophageal submucosal glands in a porcine model of esophageal injury and repair. Am J Physiol Gastrointest Liver Physiol (2017) 0.76
Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. Gastrointest Cancer Res (2012) 0.76
Bulk Genotyping of Biopsies Can Create Spurious Evidence for Hetereogeneity in Mutation Content. PLoS Comput Biol (2016) 0.76
Origin of Barrett's Epithelium: Esophageal Submucosal Glands. Cell Mol Gastroenterol Hepatol (2017) 0.75
Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples. BMC Res Notes (2017) 0.75
Deoxycholic acid (DCA) confers an intestinal phenotype on esophageal squamous epithelium via induction of the stemness-associated reprogramming factors OCT4 and SOX2. Cell Cycle (2016) 0.75
From Reflux Esophagitis to Esophageal Adenocarcinoma. Dig Dis (2016) 0.75
The Barrett's Gland in Phenotype Space. Cell Mol Gastroenterol Hepatol (2014) 0.75
Squamous cell carcinoma after radiofrequency ablation for Barrett's dysplasia. World J Gastroenterol (2014) 0.75
Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimens. World J Gastroenterol (2014) 0.75
Hnf4α is a key gene that can generate columnar metaplasia in oesophageal epithelium. Differentiation (2016) 0.75
Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma. Cancer Prev Res (Phila) (2016) 0.75
Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. Sci Rep (2016) 0.75
Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. Br J Cancer (2016) 0.75
Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. Medicines (Basel) (2017) 0.75
Porcine Esophageal Submucosal Gland Culture Model Shows Capacity for Proliferation and Differentiation. Cell Mol Gastroenterol Hepatol (2017) 0.75
Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence. Nat Rev Cancer (2017) 0.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Barrett's metaplasia. Lancet (2000) 2.47
Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology (1993) 2.32
Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res (2004) 2.15
p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res (2001) 2.06
Retinoic acid-induced glandular differentiation of the oesophagus. Gut (2006) 1.75
Experimental columnar metaplasia in the canine oesophagus. Br J Surg (1988) 1.61
p53-mutant clones and field effects in Barrett's esophagus. Cancer Res (1999) 1.61
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (1999) 1.44
Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterology (1997) 1.41
Stem cells of the oesophageal epithelium. J Cell Sci (2002) 1.36
The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol (1998) 1.25
The ulceration-associated cell lineage (UACL) reiterates the Brunner's gland differentiation programme but acquires the proliferative organization of the gastric gland. J Pathol (1994) 1.23
Neosquamous epithelium does not typically arise from Barrett's epithelium. Clin Cancer Res (2006) 1.14
On the histogenesis of Barrett's oesophagus and its associated squamous islands: a three-dimensional study of their morphological relationship with native oesophageal gland ducts. J Pathol (2005) 1.10
Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol (2005) 1.10
Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther (1999) 0.95
On the origin of cardiac mucosa: a histological and immunohistochemical study of cytokeratin expression patterns in the developing esophagogastric junction region and stomach. World J Gastroenterol (2005) 0.87
Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells. Proc Natl Acad Sci U S A (1991) 4.48
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell (1999) 4.38
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother (2001) 3.33
Hepatocytes from non-hepatic adult stem cells. Nature (2000) 3.27
The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol (1990) 3.23
Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature (1990) 3.20
Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol (2001) 3.04
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Acupressure and the prevention of nausea and vomiting after laparoscopy. Br J Anaesth (1999) 2.77
T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol (1997) 2.76
BINOCULAR VISION IN MINERS. Br J Ophthalmol (1948) 2.73
The mutation rate and cancer. Proc Natl Acad Sci U S A (1996) 2.73
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett (1998) 2.49
Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet (1999) 2.41
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet (1990) 2.22
Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science (1996) 2.22
Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest (1999) 2.10
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS (1996) 2.03
Changes in keratan sulphate levels in the serum of a long distance runner. Br J Rheumatol (1990) 2.03
Pollination biology in a lowland dipterocarp forest inSarawak, Malaysia. I. Characteristics of the plant-pollinator communityin a lowland dipterocarp forest. Am J Bot (1998) 2.00
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98
Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology (1993) 1.97
Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet (1999) 1.93
Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem (2000) 1.93
Evidence for evolution of canine parvovirus type 2 in Italy. J Gen Virol (2001) 1.88
Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.81
Dehydration of a phosphonate substrate analogue by glycerol 3-phosphate dehydrogenase. Biochem J (1974) 1.80
Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut (2006) 1.78
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol (1992) 1.74
The effect of starvation and refeeding on cell population kinetics in the rat small bowel mucosa. J Anat (1975) 1.73
APC in the regulation of intestinal crypt fission. J Pathol (1998) 1.73
Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.70
Nicotinic receptor-mediated catecholamine secretion from individual chromaffin cells. Chemical evidence for exocytosis. J Biol Chem (1990) 1.68
Crypt fission in the small intestine and colon. A mechanism for the emergence of G6PD locus-mutated crypts after treatment with mutagens. Am J Pathol (1995) 1.64
Virtual outreach: economic evaluation of joint teleconsultations for patients referred by their general practitioner for a specialist opinion. BMJ (2003) 1.62
The kinetics of villus cell populations in the mouse small intestine. I. Normal villi: the steady state requirement. Cell Tissue Kinet (1982) 1.60
Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut (2002) 1.60
Coordinated localisation of mucins and trefoil peptides in the ulcer associated cell lineage and the gastrointestinal mucosa. Gut (2000) 1.59
Thyroid FNA and benign thyroid disease. Lancet (2000) 1.59
Long-term results of pediatric liver transplantation: an analysis of 569 transplants. Ann Surg (1998) 1.59
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS (2001) 1.59
Gastrointestinal Kaposi's sarcoma: CD117 expression and the potential for misdiagnosis as gastrointestinal stromal tumour. Histopathology (2008) 1.58
Stem cell in gastrointestinal structure and neoplastic development. Gut (2004) 1.57
The metaphase arrest technique. A critical review. Cell Tissue Kinet (1980) 1.57
Experimental alveolar lipo-proteinosis following the inhalation of silica. J Pathol (1970) 1.56
The ulcer-associated cell lineage: the gastrointestinal repair kit? J Pathol (1993) 1.56
Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology (1993) 1.55
The stem cells of small intestinal crypts: where are they? Cell Prolif (2009) 1.55
Inhibition of virus protein glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells. J Gen Virol (1989) 1.54
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis (2004) 1.54
Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J Pathol (1999) 1.53
Switchable Polymer Based Thin Film Coils as a Power Module for Wireless Neural Interfaces. Sens Actuators A Phys (2007) 1.52
Endocrine cells of the human gastrointestinal tract have no proliferative capacity. Histochem J (1995) 1.49
Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer (1993) 1.49
RANTES is a chemotactic and activating factor for human eosinophils. J Immunol (1993) 1.49
hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci U S A (1993) 1.48
Pre-admission clinic in an orthopaedic department: evaluation over a 6-month period. J R Coll Surg Edinb (1998) 1.46
Delayed health hazards of pesticide exposure. Annu Rev Public Health (1986) 1.45
Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation. Antimicrob Agents Chemother (2002) 1.45
Fluoroquinolone pharmacodynamics. Clin Infect Dis (2001) 1.45
Prosthodontic rehabilitation of midfacial defects. J Prosthet Dent (1985) 1.44
Duration of acetowhitening as a novel objective tool for diagnosing high risk neoplasia in Barrett's esophagus: a prospective cohort trial. Endoscopy (2013) 1.44
Circulating mesenchymal stem cells. Int J Biochem Cell Biol (2004) 1.43
Identification of a novel VP4 genotype carried by a serotype G5 porcine rotavirus strain. Virology (2005) 1.42
Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol (2008) 1.41
Trefoil peptides. Gut (1999) 1.41
Etched carbon-fiber electrodes as amperometric detectors of catecholamine secretion from isolated biological cells. Anal Chem (1991) 1.40
Colo-anal intussusception in an adult: case report and review of the literature. Int J Clin Pract (2009) 1.40
Modification in sucrose tolerance test with acarbose, guargum and their combination in patients with non-insulin dependent diabetes. J Assoc Physicians India (1993) 1.39
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis (2001) 1.38
Molecular classification and genetic pathways in hyperplastic polyposis syndrome. J Pathol (2007) 1.38
Intestinal stem cells. J Cell Mol Med (2005) 1.37
Congenital ectropion uveae with glaucoma. Ophthalmology (1984) 1.37
The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem (1998) 1.36
Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut (1987) 1.36
Heterogeneity within the hemagglutinin genes of canine distemper virus (CDV) strains detected in Italy. Vet Microbiol (2006) 1.36
The effect of altered luminal nutrition on cellular proliferation and plasma concentrations of enteroglucagon and gastrin after small bowel resection in the rat. Br J Surg (1982) 1.36
A study of ras gene mutations in colonic adenomas from familial polyposis coli patients. Oncogene (1988) 1.35
A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother (2000) 1.32
Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut (2003) 1.32
Zones of exocytotic release on bovine adrenal medullary cells in culture. J Biol Chem (1994) 1.32
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer (2011) 1.30
TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci U S A (2006) 1.30
ABC of colorectal cancer. Molecular basis for risk factors. BMJ (2000) 1.30
Endotoxin and acute renal failure associated with obstructive jaundice. Br Med J (1970) 1.28
Does dietary fibre stimulate intestinal epithelial cell proliferation in germ free rats? Gut (1989) 1.28
The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med (1992) 1.27
Surveillance of work-related asthma in selected U.S. states using surveillance guidelines for state health departments--California, Massachusetts, Michigan, and New Jersey, 1993-1995. MMWR CDC Surveill Summ (1999) 1.27
Oxidative stress and the ovary. J Soc Gynecol Investig (2001) 1.27
Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest (1983) 1.26